Literature DB >> 3486288

Interleukin 2 production and responsiveness in active and inactive rheumatoid arthritis.

R M McKenna, W Ofosu-Appiah, R J Warrington, J A Wilkins.   

Abstract

The interleukin 2 (IL-2) production and responsiveness of peripheral blood lymphocytes from patients with rheumatoid arthritis (RA) with active or inactive disease was compared with that of normal control donors. IL-2 production was assessed using a cellular interleukin assay in which an IL-2 dependent cell line was cocultured with varying numbers of irradiated IL-2 producing lymphocytes from the different donor sources. Cells from patients with active disease showed a significantly different pattern of IL-2 production from that of control or inactive RA patients in that a lower number of cells supported growth of the IL-2 dependent cell line. In one patient this shift in pattern was shown to correlate with change in disease activity. Lymphocyte responsiveness to IL-2 as determined by limiting dilution analysis did not differ significantly between the different groups. The results are consistent with a hyperproduction of IL-2 in RA during active disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486288

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Immunoregulatory lymphokines in rheumatoid joints. II. Production by and responsiveness to interleukin-2 of eluted synovial tissue cells.

Authors:  J Hovdenes; T Egeland
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

2.  Interleukin-2 production in early rheumatoid arthritis.

Authors:  H G Taylor; N B Nixon; P T Dawes
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

3.  Immunotherapy of collagen-induced arthritis by a T-cell antiproliferative molecule.

Authors:  D J Spannaus-Martin; R Holmdahl; T F Kresina
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

4.  IL-2 production in the autologous mixed lymphocyte reaction of patients with juvenile rheumatoid arthritis.

Authors:  K Oen; R Warrington; A M Rosenberg; D Krzekotowska
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.